Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...
The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...
The U.S. FDA’s March 4, 2025, warning letter to Dexcom Inc. is a well-detailed but heavily redacted document explaining the agency’s misgivings about procedures such as monitoring of acetaminophen ...
Zacks Investment Research on MSN1d
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 ApprovalDexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the ...
Hosted on MSN11mon
Dexcom vs. FreeStyle Libre: What to Know About These CGMsThe sensor is inserted underneath the skin ... Available Dexcom CGM products include: Dexcom G6 (adults and children 2 years and older) Dexcom G7 (adults and children 2 years and older) Dexcom ...
Dexcom (Nadsaq:DXCM) today announced new insulin delivery integrations and updates on enhanced continuous glucose monitors ...
Dexcom has ceased distribution of G7 sensors with the component, but the company’s response did not address affected G6 sensors. J.P. Morgan analyst Robbie Marcus wrote in a research note ...
DexCom DXCM is facing regulatory scrutiny following ... The agency also flagged issues related to how the company addressed a deficiency in G6 sensors, which are linked to dissolved oxygen content ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback